Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
Biophytis announces that it has entered exclusive negotiations with a leading Chinese pharmaceutical company. The purpose of these discussions is to finalize a licensing agreement to co-develop and commercialize BIO101 (20-Hydroxyecdysone) in China for its most promising and advanced indications: viral respiratory infections, sarcopenia, and obesity.
The pharmaceutical company is part of an important Chinese group and stands out for its expertise in the development of innovative technologies and its ability to access a rapidly growing market.
“The entry into exclusive discussions with this pharmaceutical company marks a major first step, validating our partnership strategy in continuity with the agreement signed with Blanver for the LATAM region. The opportunity in China is huge, with obesity affecting 70 million patients and sarcopenia nearly 30 million. China is now the second-largest pharmaceutical market in the world, valued at $190 billion.” said Edouard Bieth, Chief Business Officer of Biophytis.
“This partnership could enable us to enter a new era for the company by finalizing the development of BIO101, allowing millions of patients to benefit from our therapeutic innovation.” said Stanislas Veillet, CEO of Biophytis.